CN108866182A - Application of the long-chain non-coding RNA as Alzheimer disease detection marker - Google Patents
Application of the long-chain non-coding RNA as Alzheimer disease detection marker Download PDFInfo
- Publication number
- CN108866182A CN108866182A CN201810955396.3A CN201810955396A CN108866182A CN 108866182 A CN108866182 A CN 108866182A CN 201810955396 A CN201810955396 A CN 201810955396A CN 108866182 A CN108866182 A CN 108866182A
- Authority
- CN
- China
- Prior art keywords
- alzheimer disease
- neat1
- chain non
- coding rna
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses long-chain non-coding RNAs the application in Alzheimer disease detection marker.Present invention discover that the specific long-chain non-coding RNA conspicuousness up-regulated expression in patients with Alzheimer disease, clinical assistant diagnosis technology currently used for Alzheimer disease is not perfect, and expression of expression of the specific long-chain non-coding RNA in Alzheimer disease compared with healthy person is obviously raised, this prompts specific long-chain non-coding RNA to have the potential as diagnosis of Alzheimer disease or auxiliary diagnosis marker；Also prompted specific long-chain non-coding RNA that there is the potential for becoming treatment Alzheimer disease Effective target site；Illustrate that the potential value of inhibitor great clinical application in the pharmaceutical composition of preparation treatment Alzheimer disease of specific long-chain non-coding RNA, the present invention provide new drug and method for effective treatment of Alzheimer disease.
Description
Technical field
The invention discloses long-chain non-coding RNAs the application in Alzheimer disease detection marker.
Background technique
Alzheimer disease (Alzheimer Disease, AD) is a kind of nerveous system of the progress sexual development of onset concealment
System degenerative disease.Clinically with memory disorders, aphasia, appraxia, agnosia, visual space technical ability damage, execute dysfunction and
The performance of the generalized dementias such as personality and behavior change is characterized, and the cause of disease is unknown so far.Patient was sent out before 65 years old, claimed presenile silly
It is slow-witted；Hair patient claims senile dementia after 65 years old.Patient can usually survive 8 to 10 years after symptom appearance, but the course of disease of disease
It can be 1 to 25 year.Death is usually caused by pneumonia, malnutrition or general body consumption (activity).2015, the whole world was dull-witted
Patient numbers are up to 46,800,000 people, and wherein 50%-75% is patients with Alzheimer disease, there is about 9,900,000 new hair dementia patients
It will be diagnosed, average every 3 seconds newly-increased 1 people, it is contemplated that will be up to 1.31 hundred million people to the year two thousand fifty.Studies have shown that senile dementia is after swollen
Cause the fourth-largest cause of disease of the elderly's death after tumor, heart disease, cerebrovascular disease, spending in all diseases ranked third position.With
The aging of China human mortality, patients with Alzheimer disease continue to increase.Currently, China about 6,000,000 patients, quantity occupies complete
First of ball, and every annual has 300,000 new cases, and one of the country that global speedup is most fast.Alzheimer disease may
It is one group of different substantiality disease, is related to several factors, such as heredity, wound, virus infection, other diseases, but its pathogenesis
It is unclear that one of main mechanism is beta-secretase l (β-site amyloid precursor protein-cleaving
Enzyme, BACE1) crack the amyloid plaques that amyloid precursor protein (amyloid precursor protein, APP) is formed
In neuron aggregates, A β is broken42/Aβ40Equilibrium state, generate neurotoxicity.
With the continuous research to AD, it was found that a series of long non-coding RNA of unconventionality expressions, morbidity and progress with AD
It is closely related.Long-chain non-coding RNA (lncRNA) is the non-coding RNA that length is more than 200 nucleotide.Recent study hair
Existing, long-chain non-coding RNA plays key effect in the pathogenesis of cell development, function maintenance, apoptosis and disease.LncRNA
Can in several ways in the expression of each stage controlling gene, including chromatin modification, the transcription of gene, the translation of mRNA and
Epigenetic regulation, in addition, lncRNA can also inhibit the expression of miRNA as competitiveness endogenous RNA in conjunction with miRNA.
Long-chain non-coding RNA plays a significant role in the bioprocess such as nervous system development, neuron differentiation, synaptic plasticity, ginseng
With the occurrence and development process of a variety of the nervous system diseases.Long non-coding BC200 has important work in Synaptic plasticity
With it is reduced in the cortex of frontal lobe of normal aging brain, and is expressed and increased in AD patient, can be different in AD early stage BC200
It often positions, be gathered in around core, and its increased horizontal and disease severity is in parallel relation.Pass through microarray data point
Analysis discovery, AD patient is compared with Healthy People, lncRNA differential expression in brain tissue, and most of is lncRNA between gene, such as：AD
The middle lncRNA n341006 obviously lowered that expresses can significantly affect proteins ubiquitin approach.Ubiquitin protein enzyme composite system is in egg
It is white to repair, play an important role in turnover and degradation, but be damaged in AD, amyloid plaques may be ubiquitin-mediating proteins degradation
The product of defect.Additionally, it is observed that cholesterol promotes A β generation, the lncRNA of up-regulation by directly affecting the metabolism of APP
N336934 is related with cholesterol.
(nuclear paraspeckle assembly transcript 1, also referred to as " core is rich in abundant turn to NEAT1
Record this 1 "), it from one on mankind's o.11 chromosome be referred to as multiple endocrine neoplasia (MEN) I type gene loci by
RNA polymerase II is transcribed.NEAT1 be do not splice, Polyadenylation, and the non-coding transcript limited by core.
There are two hypotype, NEAT1-1 (3.7kb) and NEAT1-2 (23kb) for it, have the overlap of about 3-4kB in 5 ' ends.Research hair
Existing considerable lncRNAs is located at around specific nucleome, and more outstanding is exactly NEAT1, is located at spot by subnucleus body
It (paraspeckle) is that its structure forms and maintain essential component part around.Other spot (paraspeckle) includes
Several protein factors, such as SFPQ, p54nrb, PSP1, RBM14, and SFPQ and p54nrb be directly in conjunction with NEAT1, from
And the formation of other spot (paraspeckle) is participated in jointly.Furthermore it has been reported that, NEAT1 participates in the biology mistake in regulating cell
Journey, including immune response, gene expression regulation etc..NEAT1 and the immunoreactive cell factor play in the immune response of body
Important function.The discovery such as IMAMURA NEAT1 can promote the expression of cell factor IL-8 gene.SFPQ (proline/glutamine
The splicing factor of enrichment) be other spot (paraspeckle) albumen in conjunction with NEAT1, it can in conjunction with the die body of IL-8 gene,
By inhibiting IL-8 promoter, to inhibit its transcription.And when cell by influenza virus, herpes simplex infections and
After poly I: C (polyinosine-cytidine monophosphate) stimulation, NEAT1 can induce SFPQ and be displaced to other spot from the gene promoter area IL-8
(paraspeckle), other spot (paraspeckle) is as a result caused excessively to be formed, and SFPQ weakens the inhibiting effect of the gene.
I.e. in NEAT-SFPQ-IL8 access, NEAT1 is to increase IL-8 gene expression as the negativity regulator of the upstream SFPQ, from
And it plays a significant role in inherent immunity reaction.The study found that NEAT1 is in kinds of tumors such as liver cancer, prostate cancer, neuroglia
High expression in the tissue of matter tumor, acute promyelocytic leukemia, breast cancer etc..In addition, the T cell that NEAT1 is infected in HIV-1
Middle expression is also to rise.
According to existing literature, researcher be pay close attention to variable neuronal genes each region of brain high low expression to A Er
The influence of Ci Haimo disease, and ignore influence of the RNA up-regulation in long non-coding area to Alzheimer disease；And to pathogenesis
Concern lays particular emphasis on the variation of harmful amyloid beta peptide.
Summary of the invention
To solve the above problems, the present invention passes through the study found that in AD patient specimen, and NEAT1 high is expressed,
And confirmed that there is important research significance and potential applicability in clinical practice in the confirmatory experiment of peripheral blood.
One of the objects of the present invention is to provide NEAT1 to detect or assist the application in detection Alzheimer disease.
Another object of the present invention is to provide NEAT1 to treat or assist in the treatment of the application in Alzheimer disease.
The technical solution adopted by the present invention is that：
Application of the NEAT1 as Alzheimer disease detection marker.
Application of the reagent of quantitative detection NEAT1 in preparation detection or auxiliary detection Alzheimer disease product.
Further, the reagent of the quantitative detection NEAT1 is the primer or/and probe of quantitative detection NEAT1.
Further, the primer of the quantitative detection NEAT1 such as SEQ ID NO：1 and SEQ ID NO：Shown in 2.
Further, the product includes kit or chip.
It is a kind of to contain quantitative detection NEAT1's for detecting or assisting the product of detection Alzheimer disease, in the product
Reagent.
Further, the reagent of the quantitative detection NEAT1 is the primer or/and primer of quantitative detection NEAT1.
Further, the primer of the quantitative detection NEAT1 such as SEQ ID NO：1 and SEQ ID NO：Shown in 2.
Inhibit application of the reagent of NEAT1 in preparation treatment or adjuvant treatment Alzheimer disease product.
Further, the product includes medicament.
The beneficial effects of the invention are as follows：
(1) present invention discover that in patients with Alzheimer disease NEAT1 gene conspicuousness up-regulated expression, currently used for A Er
The clinical assistant diagnosis technology of Ci Haimo disease is not perfect, and expression of the NEAT1 in Alzheimer disease is compared with the table of healthy person
Up to obvious up-regulation, this prompt NEAT1 has the potential as diagnosis of Alzheimer disease or auxiliary diagnosis marker；Also it prompts
NEAT1 has the potential for becoming treatment Alzheimer disease Effective target site；Illustrate that NEAT1 inhibitor treats alzheimer ' in preparation
The potential value of great clinical application in the pharmaceutical composition of disease of writing from memory, the present invention provide for effective treatment of Alzheimer disease
New drug and method.
(2) AD disease does not have exact and efficient therapeutic scheme at present, is not probe into understand its morbidity after all
Mechanism, our data analysis conclusion is undiscovered always before, therefore can provide the indirect fact for the pathogenesis of AD disease
Argument provides an innovative clue to study its pathogenesis.
Detailed description of the invention
Fig. 1 is the expression difference that NEAT1 gene (probe 225239_at) is organized in Normal group and patient AD；
Fig. 2 is NEAT1 in healthy person (left side blue) and patients with Alzheimer disease (the right is red) periphery blood T cell
Expression；
Fig. 3 expression quantity between healthy person and the group of patients with Alzheimer disease NEAT1.
Specific embodiment
The present invention is further illustrated combined with specific embodiments below.
Embodiment 1
One, in patients with Alzheimer disease difference expression gene data analysis and screening
The data that the registration number collected from NCBI-GEO database is GSE5281 (wherein contain AD patient's corresponding gene
The data of expression), and data are analyzed using NCBI-GEO-Analyze with GEO2R tool, part point
The results are shown in Table 1 for analysis.The sequence such as SEQ ID NO of 1 middle probe 227062_AT of table:Shown in 3, the sequence of probe 225239_AT
Such as SEQ ID NO:Shown in 4.
From analysis result, it has been found that there are the gene of a large amount of differential expressions in AD patient, wherein ITPKB,
The expression of the gene upregulations such as NEAT1, SLC35E, the expression of the gene deregulations such as ATP5C1, TUBB, PSMB3.
The result of table 1.GEO2R analysis part gene
| Ranking | Probe | Adjust p value | Multiple changes log value | Gene Name |
| 1 | 225239_at | 9.1E-27 | 3.72 | NEAT1 |
| 2 | 227062_at | 1.6E-20 | 3.06 | NEAT1 |
| 3 | 235213_at | 1.2E-18 | 2.48 | ITPKB |
| 4 | 213366_x_at | 1.9E-18 | -1.87 | ATP5C1 |
| 5 | 209026_x_at | 1.9E-18 | -1.63 | TUBB |
| 6 | 201400_at | 2.4E-17 | -1.41 | PSMB3 |
| 7 | 208977_x_at | 2.5E-17 | -1.73 | TUBB4B |
| 8 | 208870_x_at | 2.9E-17 | -1.83 | ATP5C1 |
| 9 | 211714_x_at | 3.8E-17 | -1.54 | TUBB |
| 10 | 220796_x_at | 4.6E-17 | 1.63 | SLC35E1 |
Two, in AD patient difference expression gene NEAT1 verifying
According to the analysis of above-mentioned data as a result, we are further to 87 AD Patient Sample As and 74 normal reference samples
The relevant microarray data of Alzheimer disease pathologic is analyzed and is visualized, and discovery patient AD is in NEAT1 gene
Extremely significant property (p value is respectively 9.1E-27 and 1.6E-20) up-regulated expression (being shown in Table 2 and Fig. 1).
The expression quantity situation of NEAT1 genetic test in table patient 2.AD and normal person
Three, in AD patient clinical peripheral blood sample NEAT1 gene expression detection
14 patients with Alzheimer disease (AD) and 15 normal healthy controls PMBC are collected from the first affiliated hospital of Zhengzhou University
Peripheral blood is separated, is cultivated, expanding periphery blood T cell and identify purity；Extraction purification mRNA and reverse transcription synthesize cDNA, with drawing
Object F1：5'-TGCTTGGTTCTGAGVTGCGT-3'(SEQ ID NO:And F2 1):5'-CCGAGACTACTTCCCCATACAT-3'
(SEQ ID NO:2) real-time fluorescence quantitative polymerase chain reaction (Real Time qPCR) detection NEAT1 is carried out in mRNA level in-site
Expression.
Testing result is as shown in Fig. 2~3 and table 3, there it can be seen that patients with Alzheimer disease periphery blood T cell
NEAT1 gene expression dose is above healthy control group.To the analysis times type variation of each sample expression quantity data and utilize statistics t
It examines, carries out difference analysis, obtain logFC=2.21, illustrate 2 groups of differences of Alzheimer disease group Yu control group NEAT1
(p- value=5.5e-06).NEAT1 expression increases the formation of possible other spot, leads to the promotion of immune system.NEAT1 passes through
The mechanism of immune pathway takes part in the formation of Alzheimer disease.
The expression of NEAT1 in 3. healthy person of table and patients with Alzheimer disease periphery blood T cell
| Sample | Number | Expression quantity | Sample | Number | Expression quantity |
| Healthy person | 1 | 534 | Patient AD | 1 | 3778 |
| Healthy person | 2 | 615 | Patient AD | 2 | 2276 |
| Healthy person | 3 | 585 | Patient AD | 3 | 2704 |
| Healthy person | 4 | 468 | Patient AD | 4 | 2452 |
| Healthy person | 5 | 295 | Patient AD | 5 | 5822 |
| Healthy person | 6 | 509 | Patient AD | 6 | 2137 |
| Healthy person | 7 | 574 | Patient AD | 7 | 1978 |
| Healthy person | 8 | 650 | Patient AD | 8 | 4447 |
| Healthy person | 9 | 405 | Patient AD | 9 | 2547 |
| Healthy person | 10 | 675 | Patient AD | 10 | 2238 |
| Healthy person | 11 | 839 | Patient AD | 11 | 1636 |
| Healthy person | 12 | 752 | Patient AD | 12 | 1858 |
| Healthy person | 13 | 862 | Patient AD | 13 | 2745 |
| Healthy person | 14 | 613 | Patient AD | 14 | 3182 |
| Healthy person | 15 | 833 |
The above results explanation NEAT1 gene conspicuousness up-regulated expression, mesh in patients with Alzheimer disease PBMC peripheral blood
The preceding clinical assistant diagnosis technology for Alzheimer disease is not perfect, and expression of the NEAT1 in Alzheimer disease compared with
The expression of healthy person is obviously raised, this prompt NEAT1 has as the latent of diagnosis of Alzheimer disease or auxiliary diagnosis marker
Energy.This has also prompted NEAT1 to have the potential for becoming treatment Alzheimer disease Effective target site.NEAT1 inhibitor is controlled in preparation
Great clinical value in the pharmaceutical composition of Alzheimer disease is treated, is provided newly for effective treatment of Alzheimer disease
Drug and method.
The above embodiment is a preferred embodiment of the present invention, but embodiments of the present invention are not by above-described embodiment
Limitation, other any changes, modifications, substitutions, combinations, simplifications made without departing from the spirit and principles of the present invention,
It should be equivalent substitute mode, be included within the scope of the present invention.
SEQUENCE LISTING
<110>Hole, auspicious east
Poplar, space rosy clouds
<120>Application of the long-chain non-coding RNA as Alzheimer disease detection marker
<130>
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> DNA
<213>Artificial sequence
<400> 1
tgcttggttc tgagvtgcgt 20
<210> 2
<211> 22
<212> DNA
<213>Artificial sequence
<400> 2
ccgagactac ttccccatac at 22
<210> 3
<211> 790
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<222> (3)..(3)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (28)..(28)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (30)..(30)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (73)..(73)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (76)..(77)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (79)..(79)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (81)..(81)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (100)..(100)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (105)..(105)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (187)..(187)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (674)..(674)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (676)..(676)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (678)..(681)
<223> n is a, c, g, or t
<400> 3
ttnttttaaa aaggaaaggt cccttaanan cccagttttg gttaaggctt ttccagtatg 60
cccaggttgg cangcnntna naaccgcagg aacggcctgn ttgtnacaaa aaggagattg 120
actcagctgc ccttggtgca tctgactgac tatgactgct gagagattcc aaggaccctt 180
aatgccnagg gctaacctct ccatgtgcag tgagacctct ggaggaagtg tcatcctctg 240
gctttgtgtg gtactcatta tggtgcagtg cgggcatgaa atgaagacac ccaaataggc 300
ttacagatac gatatgtttt aaatgttcgt atttaacaaa aacatactga cactgtttgg 360
aaatggcaac aggaagatag caaaatgaat actaacatta cgaaaagatg aacaggtaca 420
tgttccaagg caggtggctg tgaacttcct ctgagtgaag gcatcccctc cagcaccttt 480
cagcctgcta gttaggacga cccgccgcca ccctccagga cctccagccc tgcactgcct 540
ttcctctctt ttaaataatt cttcattgag ttctaatatg taaaaaaaaa aagtttactg 600
taaagtttgc aaataaggaa atttttttta aaagtcctca gtaatcttac cagtaacaat 660
tgttatgggc acantngnnn ngggaagatt tctttggtat gcatgggata agtacatttt 720
taaacaaaaa tgggattatg ccataaattc tatttggtga ctttaatata tagtgaacac 780
cttttttaat 790
<210> 4
<211> 1624
<212> DNA
<213>Artificial sequence
<220>
<221> misc_feature
<222> (251)..(251)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (256)..(256)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (264)..(265)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (347)..(348)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (350)..(351)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (355)..(355)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (375)..(375)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (383)..(383)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (386)..(386)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (733)..(733)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (925)..(925)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1429)..(1429)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1432)..(1432)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1434)..(1434)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1436)..(1438)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1514)..(1514)
<223> n is a, c, g, or t
<220>
<221> misc_feature
<222> (1532)..(1532)
<223> n is a, c, g, or t
<400> 4
agaggttccc actctacact aatacatata aaaaaggtaa ttaagataat ataactttga 60
aaaactgact tataatgaaa tagaaatatt taatagccca gtaaccctgg aagaacctga 120
aaaagttttc aaggctgggc acagtggctc acgcttgtaa tcccagcact ttgggagact 180
gaggtgggtg gatcatatga ggaggctagg agttcgaggt cagcctggcc agcatagcga 240
aaacttgtct ntactnaaaa tacnnaaatt agtcaggcat ggtggtgcac gtctgtaata 300
ccagcttctc aggaggctga ggcacgagga tcacttgaac ccaggannan naggntgcag 360
tgagctgaga tcatnccagg gcnacngaat gagactttgt ttaaaaaaaa aaaaaagtga 420
cttgatttaa gggaaaaaat gactggctat attcagtcag atatggcaaa aagtctcaag 480
gtgttaatgt gaatgattaa ggtcttgggg ggggtgtccc ctatcagact acaggtgttt 540
agaggcacag aaaaaggtgc agttgggttc ttaatgtgaa atgatgagaa gcacaactcc 600
agtgtgtctc tttgtgtaga atgtcagcag acaccccctg ctagatgtgc tggatcatgg 660
gaaagcattt ccatttgtta ctagattgtt cagaagtttt aatttatgat gggtgtggtg 720
gctcatgcct gtngtcccag cactgtggga ggctgaggca ggaggatcat ctgaggccaa 780
gagttcaaga tcagcctggg caacatagtg ataccctatc tcttaaaaaa gaagaagttt 840
ttaaatttga aataataata ggtactggat ttatgcaaat gtcttttctg cgtcttttga 900
gatgagtatc aggttttttt ttttnccttt tatcatctga tgatgaactt aatgtttcca 960
tttgtattaa tggaatacta agtccctctg tgatttctga accaagctat tcctaggcct 1020
gagttttatt ttgttgacac agaaataaat tagaaggcca agcgtggtgg catgtgcctg 1080
tagtcctagt tgctgaggta agaggattgc ttgagcccag gagttcaagg ctgcagcaag 1140
ctttgattgc gccactgcac tccagccttg gcgacagact aagacgctgt ctcaaaaaaa 1200
aacaaaaacg acaaaaaaaa aacaaaacag aaaaaataaa ctaaggcaat gacagtccct 1260
ggcaaatgct gggagggagg cagcagtggt cagggaaggt aaccctgaag caggacttgt 1320
aaagcaaata agattgggag gccaaggtgg gtggatcacg aggtcaggag ttcgagacca 1380
gcctggccaa catagtgaaa ccccgtcttt actaaaaata caaaaaaant ancnannngt 1440
ggtggtgggt gcctgtagtc ccagctactt gggaggctga ggcaggagaa tctcgaaccc 1500
aggaggcgga ggtnacagtc agctgagacc gnaccattgc actccagcct gggtgacaga 1560
gcaagattcc gtctcaaaaa aaaaaaaaaa aaaaaaaaag ggcggccgct ctagagtatc 1620
cctc 1624
Claims (10)
1. application of the long-chain non-coding RNA NEAT1 as Alzheimer disease detection marker.
2. application of the reagent of quantitative detection NEAT1 in preparation detection or auxiliary detection Alzheimer disease product.
3. application according to claim 1, which is characterized in that the reagent of the quantitative detection NEAT1 is quantitative detection
The primer or/and probe of NEAT1.
4. application according to claim 3, which is characterized in that the primer of the quantitative detection NEAT1 such as SEQ ID NO：1
With SEQ ID NO：Shown in 2.
5. application according to claim 2, which is characterized in that the product includes kit or chip.
6. a kind of for detecting or assisting the product of detection Alzheimer disease, which is characterized in that contain quantitative inspection in the product
Survey the reagent of NEAT1.
7. product according to claim 6, which is characterized in that the reagent of the quantitative detection NEAT1 is quantitative detection
The primer or/and probe of NEAT1.
8. product according to claim 7, which is characterized in that the primer of the quantitative detection NEAT1 such as SEQ ID NO：1
With SEQ ID NO：Shown in 2.
9. inhibiting application of the reagent of NEAT1 in preparation treatment or adjuvant treatment Alzheimer disease product.
10. application according to claim 9, which is characterized in that the product includes medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810955396.3A CN108866182A (en) | 2018-08-21 | 2018-08-21 | Application of the long-chain non-coding RNA as Alzheimer disease detection marker |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810955396.3A CN108866182A (en) | 2018-08-21 | 2018-08-21 | Application of the long-chain non-coding RNA as Alzheimer disease detection marker |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108866182A true CN108866182A (en) | 2018-11-23 |
Family
ID=64321006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810955396.3A Pending CN108866182A (en) | 2018-08-21 | 2018-08-21 | Application of the long-chain non-coding RNA as Alzheimer disease detection marker |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108866182A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111690739A (en) * | 2020-07-31 | 2020-09-22 | 上海市精神卫生中心（上海市心理咨询培训中心） | MCI diagnostic marker, MCI diagnostic kit and corresponding detection method |
| CN112143801A (en) * | 2020-10-13 | 2020-12-29 | 济南帕斯维德生物科技有限公司 | Biomarker for early diagnosis of Alzheimer's disease |
| CN113234812A (en) * | 2021-06-09 | 2021-08-10 | 济南帕斯维德生物科技有限公司 | Diagnostic reagent for diagnosing Alzheimer disease |
| CN113345580A (en) * | 2021-07-21 | 2021-09-03 | 河北医科大学第二医院 | Alzheimer disease detection reagent, diagnosis device and application |
| CN113350367A (en) * | 2021-06-02 | 2021-09-07 | 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) | Application of long-chain non-coding RNA-NEAT1, adeno-associated virus for over-expressing RNA-NEAT1 and application |
| CN113368260A (en) * | 2021-06-09 | 2021-09-10 | 济南帕斯维德生物科技有限公司 | Pharmaceutical preparation for treating Alzheimer disease |
| CN113862346A (en) * | 2021-09-26 | 2021-12-31 | 北京大学 | Use of long non-coding RNA in treating Alzheimer's disease |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014177867A2 (en) * | 2013-05-03 | 2014-11-06 | Nottingham Trent University | Biomarkers |
-
2018
- 2018-08-21 CN CN201810955396.3A patent/CN108866182A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014177867A2 (en) * | 2013-05-03 | 2014-11-06 | Nottingham Trent University | Biomarkers |
Non-Patent Citations (2)
| Title |
|---|
| SPREAFICO M,ET AL.: "Rusconi F,et al.Multiple layers of CDK5R1 regulation in Alzheimer"s disease implicate long noncoding RNAs.International Journal of Molecular Sciences", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
| 李新华等: "银屑病患者外周血T细胞SCL及NEAT1的表达", 《中国药物与临床》 * |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113667737A (en) * | 2020-07-31 | 2021-11-19 | 上海市精神卫生中心（上海市心理咨询培训中心） | MCI diagnostic marker, MCI diagnostic kit and corresponding detection method |
| CN111690739B (en) * | 2020-07-31 | 2022-09-16 | 上海市精神卫生中心（上海市心理咨询培训中心） | MCI diagnostic marker, MCI diagnostic kit and corresponding detection method |
| CN111690739A (en) * | 2020-07-31 | 2020-09-22 | 上海市精神卫生中心（上海市心理咨询培训中心） | MCI diagnostic marker, MCI diagnostic kit and corresponding detection method |
| WO2022022060A1 (en) * | 2020-07-31 | 2022-02-03 | 上海市精神卫生中心（上海市心理咨询培训中心） | Mci diagnostic marker, mci diagnostic kit, and corresponding detection method |
| CN114832108A (en) * | 2020-10-13 | 2022-08-02 | 济南帕斯维德生物科技有限公司 | Medicine for treating Alzheimer disease |
| CN112143801A (en) * | 2020-10-13 | 2020-12-29 | 济南帕斯维德生物科技有限公司 | Biomarker for early diagnosis of Alzheimer's disease |
| CN114832108B (en) * | 2020-10-13 | 2024-03-22 | 澜杉(北京)生物科技有限公司 | Alzheimer disease treatment drug |
| CN113350367A (en) * | 2021-06-02 | 2021-09-07 | 山东第一医科大学附属青岛眼科医院(山东省眼科研究所、青岛眼科医院) | Application of long-chain non-coding RNA-NEAT1, adeno-associated virus for over-expressing RNA-NEAT1 and application |
| CN113368260A (en) * | 2021-06-09 | 2021-09-10 | 济南帕斯维德生物科技有限公司 | Pharmaceutical preparation for treating Alzheimer disease |
| CN113234812A (en) * | 2021-06-09 | 2021-08-10 | 济南帕斯维德生物科技有限公司 | Diagnostic reagent for diagnosing Alzheimer disease |
| CN113234812B (en) * | 2021-06-09 | 2023-11-03 | 科德角国际生物医学科技(北京)有限公司 | Diagnostic reagent for diagnosing Alzheimer's disease |
| CN113345580A (en) * | 2021-07-21 | 2021-09-03 | 河北医科大学第二医院 | Alzheimer disease detection reagent, diagnosis device and application |
| CN113862346A (en) * | 2021-09-26 | 2021-12-31 | 北京大学 | Use of long non-coding RNA in treating Alzheimer's disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108866182A (en) | Application of the long-chain non-coding RNA as Alzheimer disease detection marker | |
| Lin et al. | Role of calcium signaling pathway-related gene regulatory networks in ischemic stroke based on multiple WGCNA and single-cell analysis | |
| WO2021088317A1 (en) | Mirna marker for diagnosis and/or treatment of alzheimer's disease | |
| Li et al. | Integration of gene expression profile data to screen and verify hub genes involved in osteoarthritis | |
| Shi et al. | MicroRNA expression signature in degenerative aortic stenosis | |
| Han et al. | Lipopolysaccharide alters the m6A epitranscriptomic tagging of RNAs in cardiac tissue | |
| Bisht et al. | An integrated approach to unravel a putative crosstalk network in Alzheimer’s disease and Parkinson’s disease | |
| Wu et al. | Osteoblast-derived lipocalin-2 regulated by miRNA-96-5p/Foxo1 advances the progression of Alzheimer’s disease | |
| Ou et al. | Construction of long noncoding RNA-associated ceRNA networks reveals potential biomarkers in Alzheimer’s disease | |
| Yang et al. | Comprehensive analysis of lncRNA expression profiles in rats with cerebral ischemia-reperfusion injury after treatment with 20 (R)-ginsenoside Rg3 | |
| Zheng et al. | PIK3R1, SPNB2, and CRYAB as potential biomarkers for patients with diabetes and developing acute myocardial infarction | |
| Zhao et al. | Transcriptional regulatory network during axonal regeneration of dorsal root ganglion neurons: laser-capture microdissection and deep sequencing | |
| CN108588214A (en) | Joint AβWith the AD model mouse hippocampus gene expression difference spectrums and its assay method of D-gal structures and application | |
| Tang et al. | lncRNA-associated competitive endogenous RNA Regulatory Network in an Aβ25-35-Induced AD mouse model treated with tripterygium glycoside | |
| Yang et al. | Biomarker identification of thyroid associated ophthalmopathy using microarray data | |
| Lee et al. | Genome-wide analysis of a cellular exercise model based on electrical pulse stimulation | |
| Zhang et al. | Astragaloside IV Reduces OxLDL‐Induced BNP Overexpression by Regulating HDAC | |
| Zeinelabdeen et al. | MIAT LncRNA: A multifunctional key player in non-oncological pathological conditions | |
| Wang et al. | Network pharmacology and molecular docking-based strategy to investigate the multitarget mechanisms of Shenqi Yizhi granule on Alzheimer’s disease | |
| Huang et al. | Cell type-and region-specific translatomes in an MPTP mouse model of Parkinson's disease | |
| Jiang et al. | Anti‐rheumatoid arthritis effects of Xanthii Fructus by affecting the PI3K‐AKT signaling pathway based on TMT‐labeled quantitative proteomics | |
| Ge et al. | Potential blood biomarkers for chronic traumatic encephalopathy: The multi-omics landscape of an observational cohort | |
| Zhang et al. | Deciphering the dynamic niches and regeneration-associated transcriptional program of motoneurons following peripheral nerve injury | |
| Xu et al. | Integrated analyses reveal evolutionarily conserved and specific injury response genes in dorsal root ganglion | |
| Hu et al. | Study on the role of calcium channel protein TRPV4 in the inflammatory pathway of type 2 diabetic adipose tissue based on gene databases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20181123 |
|
| RJ01 | Rejection of invention patent application after publication |